Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal ...
Please provide your email address to receive an email when new articles are posted on . “We felt that it would be important to investigate the levels of the immune checkpoint protein PD-L2 in breast ...
July 28, 2011 — The latest update of long-term data on tamoxifen in early-stage breast cancer confirm and further define the benefit of the drug. In women with estrogen-receptor (ER)-positive disease, ...
Giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer, marking a milestone in SERD regimen trials. The trial met co-primary endpoints, benefiting patients ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...
– ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment – – Data will be featured in ...
– Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years – – ER-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback